Drug Profile


Alternative Names: Beta-D-Glc-IPM; D 19575; β-D-Glc-IPM

Latest Information Update: 11 May 2016

Price : $50

At a glance

  • Originator Baxter Oncology; German Cancer Research Center
  • Developer Baxter Oncology; Eleison Pharmaceuticals; MediBIC; Threshold Pharmaceuticals
  • Class Antineoplastics; Phosphoramide mustards; Small molecules
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase I Solid tumours
  • Discontinued Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma

Most Recent Events

  • 05 May 2016 Phase-III clinical trials in Pancreatic cancer (metastatic disease, Second-line therapy or greater) in China (IV)
  • 05 May 2016 Eleison Pharmaceuticals receives approval from the China Food and Drug Administration (CFDA) to enrol patients in China for a phase III trial in Pancreatic cancer
  • 11 Dec 2015 Eleison receives patent allowance for glufosfamide in United States
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top